Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02516670
Other study ID # J15106
Secondary ID NCI-2015-01169IR
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 20, 2016
Est. completion date October 14, 2021

Study information

Verified date June 2023
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid (vitamin C) is a water-soluble vitamin that may help inhibit the growth of cancer cells. It is not yet known whether docetaxel works better when given with or without ascorbic acid in treating prostate cancer.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date October 14, 2021
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have metastatic castration-resistant prostate cancer (prostate cancer progressing despite castrate levels of testosterone [< 50 ng/dL] using standard measures of progression defined by Prostate Cancer Working Group 2), are chemo-naïve for metastatic castration-resistant prostate cancer (mCRPC); patients must have symptomatic disease or visceral metastases or otherwise be eligible for docetaxel treatment per investigator judgment (e.g. for progression on imaging or rapidly rising PSA despite 2nd line hormonal treatment); - Note: Six cycles of prior docetaxel are allowed in hormone-sensitive disease, per Eastern Cooperative Oncology Group (ECOG) 3805 data and have been off of docetaxel for at least 12 months - Have a pathological diagnosis of prostate carcinoma - Patients may be receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone < 50 ng/dL - Patient may be receiving bone targeted agents - Have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 2 (PCWG2) criteria - Have ECOG performance status 0-1 - Have an estimated life expectancy > 4 months - Absolute neutrophil count >= 1500/mm^3 - Platelets >= 100,000/mm^3 - Hemoglobin >= 9 g/dL - Total bilirubin =< 1.0 upper limit of normal (ULN) - Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN - Creatinine =< 1.6 mg/dl (for patients with > 1.6 mg/dl, calculated or measured creatinine clearance must be >= 55 mL/minute [Cockcroft-Gault]) - Men of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 30 days after discontinuation of study treatment - If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur - Have the ability to understand, and have given written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care Exclusion Criteria: - Have had known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for CNS involvement for at least one week prior to trial treatment; patients with primary brain tumors are not eligible; however, as patients are completing abiraterone therapy, they will be allowed to continue up to 10 mg/day of prednisone - Have had prior chemotherapy for metastatic disease in castration-resistant prostate cancer (prior chemotherapy for hormone-sensitive disease, more than twelve months prior to registration, is acceptable) - Have had had surgery within four weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement - Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug - Have received other investigational drugs within 28 days prior to enrollment - Is expected to require any other form of systemic or localized antineoplastic therapy while on study - Patients who require frequent (several times a day) monitoring of their blood glucose or patients who have recently been hospitalized for glucose control - Are being treated with anticoagulation therapy (aspirin and nonsteroidal anti-inflammatory drugs [NSAIDS] are allowed) - The subject requires concomitant treatment with the following inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4): - Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin - Antifungals: itraconzaole, ketoconazole, voriconazole, fluconazole, posaconazole - Antidepressants: nefazodone - Antidiuretic: conivaptan - Anti-retrovirals: delaviridine or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) or cobicistat-boosted antiretrovirals - Gastrointestinal (GI): cimetidine, aprepitant - Hepatitis C: boceprevir, telaprevir - Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids - Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Has glucose-6-phosphate dehydrogenase (G6PD) deficiency - Have end stage renal disease - Has history of calcium oxalate stones - Has history of iron overload - Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) - Have a know active uncontrolled hepatitis B, or hepatitis C infection

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Ascorbic Acid
Given IV
Drug:
Docetaxel
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Placebo
Given IV
Quality-of-Life Assessment
Ancillary studies

Locations

Country Name City State
United States Anne Arundel Health System, Research Institute Annapolis Maryland
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States University Hospitals of Cleveland Seidman Cancer Center Cleveland Ohio
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Sibley Memorial Hospital Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Effect of Ascorbic Acid on Docetaxel Exposure To determine whether ascorbic acid alters docetaxel exposure and compare between treatment arms, pharmacokinetics samples will be collected prior to, during, and after ascorbic acid and docetaxel infusions. Up to 24 weeks
Other F2-isoprostanes, a Pharmacodynamic Measure of Oxidant Injury in Vivo Correlative analyses will assess the association between ascorbic acid and lipid peroxidation (F2-isoprostanes) in the two study arms, globally, and over time. Comparisons of ascorbic acid and F2-isoprostanes by study arm at cycle 1, cycle 2, cycle 4 and cycle 6, accounting for baseline measures obtained from the same patient, will be made by taking differences between post baseline and baseline values and comparing these differences between arms of the study with t-tests. Regression will also be used to assess the association between F2-isoprostane and ascorbic acid at cycle 4 and at cycle 6. Up to course 6 (18 weeks)
Other Peak and Trough Ascorbic Acid Levels Up to 24 weeks
Primary Number of Participates With a Decline in Prostate-specific Antigen From Their Baseline Measurement prostate-specific antigen decline will be defined as = 50% from baseline measurement up to 24 weeks
Primary Number of Participants With Adverse Events Number of participants experiencing fatigue, nausea, bone pain, and anorexia as defined by CTCAE 4.0 Up to 30 days after the last dose of study drug
Secondary Average Number of Times Docetaxel Had Dose Reductions The number of dose reductions and total number of completed cycles will be summarized by study arm. Up to 24 weeks
Secondary Number of Serious Adverse Events Number of serious adverse events of all types as defined by Common Terminology Criteria for Adverse Events 4.0.
A serious adverse event is an undesirable sign, symptom, or medical condition that:
Results in death
Is life threatening
Requires inpatient hospitalization or causes prolongation of existing hospitalization for >24 hours
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event
Up to 30 days after last dose of study drug
Secondary Number of Participates Experiencing Serious Adverse Events (SAE) Number of serious adverse events defined as grade 3 or higher (fatigue, nausea, bone pain, and anorexia) in participates as defined by CTCAE 4.0 Up to 24 weeks
Secondary Change in Quality of Life (QoL) as Measured by the FACT-P Questionnaire The (FACT-P) is made up of 39 question, with the total score ranging between 0 and 156 with 0 being the best and 156 as the worst. Up to course 6 of therapy (18 weeks)
Secondary Radiographic Progression Free Survival (rPFS) To determine the rPFS of participates that receive at least one dose of ascorbic acid compared to those who received placebo Up to 3 years
See also
  Status Clinical Trial Phase
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT01685125 - Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Completed NCT00936975 - Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases Phase 2
Completed NCT00087139 - Ixabepilone in Treating Patients With Metastatic Prostate Cancer Phase 2
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Completed NCT01881867 - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01385059 - Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer Phase 2
Terminated NCT01866423 - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02807805 - Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Phase 2
Completed NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01026623 - Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Phase 1/Phase 2
Completed NCT01682941 - Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen N/A
Terminated NCT00536991 - Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer Phase 1/Phase 2
Completed NCT00074022 - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors Phase 1/Phase 2
Completed NCT03707184 - Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Phase 2
Withdrawn NCT00003534 - Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer Phase 2
Recruiting NCT04113096 - Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer Early Phase 1
Active, not recruiting NCT03344211 - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 2
Terminated NCT02985021 - Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies Phase 2
Recruiting NCT02615223 - Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer N/A